Develops RNA-targeting medicines for people with genetic diseases, with a focus on neurological disorders.
10-K for FY2025, filed Mar 5, 2026
Earns revenue through research collaboration and license agreements.
10-K for FY2025, filed Mar 5, 2026Since our inception in 2015, we have focused substantially all of our resources primarily on developing our RAP Platform, identifying…View ↗
$3.5M
10-K for FY2025, filed Mar 5, 2026
$3.5M ↗
Works with research partners, including GlaxoSmithKline, through discovery, collaboration and license agreements.
10-K for FY2025, filed Mar 5, 2026Our primary therapeutic focus is on diseases of the central nervous system (“CNS”), where there are numerous rare and prevalent…View ↗
No. It lost $80.4M in FY2025.
Competes with Stoke Therapeutics, Acadia Pharmaceuticals, Praxis Precision Medicines, GondolaBio, Tevard Biosciences, Regel Therapeutics, Quiver Bioscience, Amgen, Ultragenyx Pharmaceutical, Arcturus Therapeutics Holdings, iECURE, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals
10-K for FY2025, filed Mar 5, 2026Companies that compete with us directly on the discovery and development of product candidates targeting SYNGAP1 include Stoke…View ↗
Loading...